证券代码：688293 证券简称：奥浦迈 公告编号：2025-104 上海奥浦迈生物科技股份有限公司 关于召开2025年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东大会召开日期：2025年12月1日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、召开会议的基本情况 （一）股东大会类型和届次 2025年第三次临时股东大会 （二）股东大会召集人：董事会 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 （四）现场会议召开的日期、时间和地点 召开日期时间：2025 年 12 月 1 日 14 点 00 分 召开地点：上海市浦东新区紫萍路 908 弄 28 号楼上海奥浦迈生物科技股份 有限公司 五楼公司会议室 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 1 日 至2025 年 12 月 1 日 采用上海证券交易所网络投票系统，通过交易 ...

一、监事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届监事会第十六次会议于2025年11月14日通过现场表决与通讯相结合的方式召 开。本次会议通知及相关资料已于2025年11月7日送达全体监事。本次会议由监 事会主席梁欠欠女士召集并主持，会议应出席监事3名，实际出席监事3名，本次 会议的召集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定，会议决议合法有效。 证券代码：688293 证券简称：奥浦迈 公告编号：2025-102 上海奥浦迈生物科技股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 务自然免除。公司《监事会议事规则》相应废止，各项制度中涉及监事、监事会 的规定不再适用。在公司股东大会审议通过取消监事会事项前，公司监事会仍将 严格按照法律、法规及规范性文件的要求继续履行监事会职责。 二、监事会会议审议情况 经与会监事审议表决，形成的会议决议如下： 1、审议通过了《关于取消监事会及废止<监事会议事规则> ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-101 上海奥浦迈生物科技股份有限公司 第二届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届董事会第十七次会议于2025年11月14日通过现场表决与通讯相结合的方式召 开。本次会议通知及相关资料已于2025年11月7日送达全体董事。本次会议由董 事长肖志华先生召集并主持，会议应出席董事7名，实际出席董事7名，本次会议 的召集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议表决，形成的会议决议如下： 2、逐项审议通过了《关于制定及修订公司部分治理制度的议案》 为进一步促进公司规范运作，维护公司及股东的合法权益，建立健全内部治 理机制，根据《公司法》《证券法》《关于新<公司法>配套制度规则实施相关过 渡期安排》《上海证券交易所科创板股票上市规则》《上海证券交 ...

Core Viewpoint - The company reported strong revenue growth and profitability in Q1-Q3 2025, indicating a robust performance trajectory in the cell culture media sector [1][2]. Financial Performance - For Q1-Q3 2025, the company achieved revenue of 272 million yuan, representing a year-on-year increase of 25.79% [1]. - The net profit attributable to shareholders reached 69 million yuan, with a year-on-year growth of 75.66% [1]. - The net profit excluding non-recurring items was 49 million yuan, reflecting an 81.48% increase year-on-year [1]. Business Segmentation - In Q3 2025, the company generated revenue of 94 million yuan, marking a 29.80% year-on-year increase [2]. - The cell culture media segment contributed 83 million yuan in Q3 2025, with a significant year-on-year growth of 48%, driven by product development and market expansion [2]. - The CDMO segment, however, saw a revenue decline of 35% year-on-year, generating 10 million yuan in Q3 2025, attributed to fluctuations in demand [2]. Future Outlook - The company is expected to continue experiencing high growth in the cell culture media business, supported by international expansion and an increasing number of domestic service pipelines [2]. - The strategic alignment between the CDMO and cell culture media businesses is anticipated to foster collaborative growth in the coming years [3]. Investment Recommendations - As a leading player in the domestic cell culture media market, the company is poised to benefit from the thriving domestic biopharmaceutical market and domestic substitution trends [3]. - Revenue forecasts for 2025-2027 have been adjusted slightly downward, with expected revenues of 374 million, 473 million, and 595 million yuan respectively [3]. - Corresponding EPS estimates have also been revised to 0.61, 0.90, and 1.29 yuan, with a PE ratio of 96, 65, and 45 times based on the closing price of 58.50 yuan per share on November 13, 2025 [3].

交易信息汇总资金流向 11月13日主力资金净流入405.26万元，占总成交额5.79%；游资资金净流入861.97万元，占总成交额 12.32%；散户资金净流出1267.24万元，占总成交额18.11%。 截至2025年11月13日收盘，奥浦迈(688293)报收于58.5元，下跌0.1%，换手率1.05%，成交量1.19万手， 成交额6998.52万元。 当日关注点 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：11月13日主力资金净流入405.26万元，占总成交额5.79%。 来自公司公告汇总：奥浦迈近日收到与收益相关的政府补助350.00万元，相关会计处理将依据审 计结果最终确认。 公司公告汇总 奥浦迈：关于获得政府补助的公告 上海奥浦迈生物科技股份有限公司于近日收到政府补助款项人民币350.00万元，属于与收益相关的政府 补助。公司根据《企业会计准则第16号——政府补助》等有关规定进行会计处理。上述政府补助未经审 计，具体会计处理及对公司2025年度财务状况的影响以审计机构年度审计结果为准。 ...

Investment Rating - The investment rating for the company is "Accumulate" [5] Core Views - The company continues to experience rapid growth, with its cell culture media business contributing significantly to performance resilience. For the first three quarters of 2025, the company achieved revenue of 272 million yuan, a year-on-year increase of 25.79%, and a net profit attributable to shareholders of 69 million yuan, up 75.66% year-on-year [2][3] - The cell culture media business saw a revenue of 83 million yuan in Q3 2025, representing a year-on-year growth of 48%, driven by product development and market expansion both domestically and internationally. In contrast, the CDMO business experienced a revenue decline of 35% in the same quarter due to demand fluctuations [2] - The company is positioned as a leader in the domestic culture media market, benefiting from the robust growth of the domestic biopharmaceutical market and domestic substitution trends. The strategic alignment between the CDMO and culture media businesses is expected to support continued high growth in the coming years [3] Financial Summary - For the fiscal year 2025, the company is projected to generate revenue of 374 million yuan, with a year-on-year growth of 25.7%. The net profit attributable to shareholders is expected to be 69 million yuan, reflecting a significant increase of 230.1% year-on-year [4][8] - The gross profit margin is anticipated to be 55% in 2025, improving to 59.5% by 2027. The earnings per share (EPS) are forecasted to be 0.61 yuan in 2025, increasing to 1.29 yuan by 2027 [4][8] - The company’s price-to-earnings (PE) ratios are projected to be 95.83 for 2025, 64.98 for 2026, and 45.21 for 2027, indicating a decreasing trend as earnings grow [4][8]

公司近日发布公告称，上海奥浦迈生物科技股份有限公司于近日收到政府补助款项人民币350.00万元， 属于与收益相关的政府补助。公司根据《企业会计准则第16号——政府补助》等有关规定进行会计处 理。上述政府补助未经审计，具体会计处理及对公司2025年度财务状况的影响以审计机构年度审计结果 为准。 最新公告列表 《奥浦迈：关于获得政府补助的公告》 截至2025年11月13日收盘，奥浦迈（688293）报收于58.5元，较前一交易日下跌0.1%，最新总市值为 66.58亿元。该股当日开盘58.86元，最高59.5元，最低57.81元，成交额达6998.52万元，换手率为 1.05%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The discussion at the Shanghai Securities Exchange International Investors Conference highlighted the potential for world-class pharmaceutical companies to emerge from China, driven by innovation, supportive policies, and collaborative teams [1][3]. Group 1: Industry Opportunities - High Fei, Chairman and General Manager of Hangzhou Aotai Biotechnology Co., believes that world-class enterprises will definitely emerge in China, emphasizing the importance of industry opportunities, international environment, and continuous innovation [3]. - Xiao Zhihua, Chairman of Shanghai Aopumai Biotechnology Co., pointed out that while challenges exist for Chinese companies to become truly global in a time of globalization retreat, he remains confident that world-class enterprises will emerge [3]. Group 2: Importance of Policy and Market - Zhang Lianshan, Global R&D President of Jiangsu Hengrui Medicine Co., stressed the significance of confidence and policy support, stating that biopharmaceutical companies must first establish value in the Chinese market to generate global value [3]. - The discussion concluded that with improved innovation capabilities and ongoing policy enhancements, the Chinese pharmaceutical industry is likely to nurture world-class enterprises in the future [3].

证券日报网讯 11月13日晚间，奥浦迈发布公告称，公司于近日收到政府补助款项人民币350.00万元，属 于与收益相关的政府补助款项。 （文章来源：证券日报） ...

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]